The Cancer Letter

Inside information on cancer research and drug development

Conversation with The Cancer Letter

USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said in its final recommendation statement April 30.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Matthew Bin Han Ong
Senior Editor
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Enhertu improves PFS in HR-positive, HER2-low breast cancer in phase III trial

Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
Byline
Matthew Bin Han Ong
Senior Editor
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account